On June 28, Der Standard published an insightful article highlighting CBmed’s innovative approaches to cancer drug development. Our dedicated team in Graz is leveraging the power of laboratory research and bioinformatics to systematically discover biomarkers, aimed at speeding up the availability of new cancer therapies.

Key Innovations:

• Integration of Classic Lab Work and Advanced Bioinformatics: By combining traditional laboratory techniques with cutting-edge bioinformatic methods, we create a systematic framework for identifying crucial biomarkers, enhancing both the efficiency and accuracy of our research.
• Strong Focus on Personalized Medicine: Our commitment to personalized medicine ensures that cancer treatments are tailored to the unique genetic profiles of individual patients, ultimately improving treatment outcomes.
• Strategic Partnership with Boehringer Ingelheim: Collaborating with industry leaders like Boehringer Ingelheim strengthens our capabilities, providing us with valuable resources and expertise to accelerate our research initiatives.

At CBmed, we believe that translational research is essential for reducing the time it takes for life-saving treatments to reach patients. Our innovative strategies are making significant strides in the fight against cancer.

To learn more about our initiatives and insights from our expert, Barbara Prietl, read the full article here: Der Standard Article. Together, we are working towards a future where effective cancer therapies are more accessible to those in need.